# MaxCyte Q3 Revenue Rises 49.3% as EPS Loss Beats Estimates By John Kim Canonical URL: https://www.tokenpost.com/news/business/53875 Published: 2026-11-11T11:24:16.000Z Updated: 2026-11-11T11:24:16.000Z Section: Business > Revenue reached $10.2 million, including $8.2 million in core revenue and $2 million tied to its SPL program. MaxCyte, Inc. posted third-quarter 2026 revenue of $10.2 million, up 49.3% year over year, while its GAAP loss per share came in narrower than estimates. Revenue exceeded estimates by $2.73 million. The company recorded a GAAP loss of 5 cents per share, 3 cents better than estimates. Core revenue was $8.2 million, and SPL program-related revenue totaled $2 million. An earlier [preliminary Q3 core revenue estimate]() put core revenue at about $8.1 million. ## Links in this article - [preliminary Q3 core revenue estimate](https://www.tokenpost.com/news/business/31865)